Introduction
Amplification of chromosomal region 20q has been reported to occur frequently in breast cancer as well as in many other cancer types (1, 2) . One of the identified candidate oncogenes in this region is AURKA (also named as BTAK or STK15 or AIK1) (3) , which encodes the serine-threonine kinase Aurora-A involved in controlling centrosome function, mitotic spindle formation and proper chromosome segregation during mitosis (4) . AURKA may function as an oncogene, since its overexpression has been shown to lead to centrosome amplification, aneuploidy and transformation of mammalian cells (5) . The essential function of Aurora-A in cell division suggests it to be a potential drug target in cancer therapy (6, 7) . In fact, Aurora-A inhibitors have been shown to inhibit tumor growth in xenograft models (8, 9) and some molecules have already entered phase I and II clinical studies (10) . However, at present there are no clinical biomarkers for Aurora-A inhibitors in breast cancer or any other cancer types.
This pilot study assesses the clinicopathological associations of AURKA gene amplification in clinical breast tumors. In addition, Aurora-A mRNA expression, gene amplification and DNA sequence variation are further characterized in a set of breast cancer cell lines.
Materials and methods

Clinical tumor specimens and breast cancer cell lines.
After receiving ethical permission, the study material consisted of a cohort of 126 consecutive primary invasive ductal breast carcinomas with tumor samples available and was obtained from Seinäjoki District Hospital, Seinäjoki, Finland. Histological typing, grading, staging and evaluation of estrogen receptor (ER) and progesterone receptor (PgR) status were done as part of routine diagnostic protocol according to standard histopathologic techniques and WHO classification. Formalin-fixed, paraffin-embedded tumor samples were then used for preparation of tissue microarrays (TMA). Detailed information on preparation of TMA blocks is available on request.
Breast cancer cell lines BT-474, MCF-7, MDA-MB-453,  MDA-MB-134-VI, MDA-MB-361, SK-BR-3, UACC-812,  UACC-893, ZR-75-1, ZR-75-30, CAMA-1 and DU4475 were obtained from The American Type Culture Collection.
Breast cancer cell line L56Br-C1 deficient in BRCA1 gene product was kindly provided by Professor Åke Borg, University of Lund, Sweden (11) . Breast cancer cell line clinically resistant to trastuzumab (Herceptin) JIMT-1 was established and characterized in our laboratory (12) and is available via DSMZ (www.dsmz.de). All the breast cancer cell lines used in this study were cultured in recommended conditions and DNA, RNA and protein extraction were done using standard procedures (11) .
In situ hybridization analyses. A PAC (P1 artificial chromosome) probe specific for the AURKA gene on chromosome 20q13 (PAC clone 189F4) and a reference probe to AURKA, a BAC (bacterial artificial chromosome) clone RP11-96L6 (a unique sequence probe located at 20p11.1-11.22) were used in the hybridization analyses. Locus 20p11.1-11.22 specific probe RP11-96L6 was used as a reference since specific chromosome 20 centromere probes are not available.
Chromogenic in situ hybridization (CISH) was carried out as previously described (13) . Briefly, TMA slides were deparaffinized and incubated in citric acid buffer (pH 6.0) at 80˚C for 1 h, followed by cooling at room temperature. Enzymatic digestion was carried out by applying 100 μl of pepsin to the slides (Digest-All III solution; Zymed, Inc., San Francisco, CA). After dehydration, a digoxigenin-labelled PAC probe specific for AURKA gene (PAC clone 189F4) or the reference probe (clone RP11-96L6) was applied to the slides. The sections were denatured on a thermal plate and hybridization was carried out overnight at 37˚C. The probes were detected by consecutive incubations with mouse antidigoxigenin (Roche Biochemicals, Mannheim, Germany), antimouse-peroxidase polymer (Powervision + ; Immunovision, Inc.) and DAB chromogen. The sections were then counterstained with hematoxylin and embedded.
The fluorescence in situ hybridization (FISH) was carried out as previously described (14) . The probe specific for the AURKA gene (PAC 189F4) and the reference probe (clone RP11-96L6) were labelled by nick-translation. Slides were hybridized with AURKA or RP11-96L6 probe as previously described (14) . In CISH and FISH analyses gene amplification of AURKA was defined as the ratio of AURKA/RP11-96L6 signals ≥2.
Immunohistochemistry (IHC).
The specificity of the primary antibody for Aurora-A (NCL-L-AK2, Novocastra Laboratories, Newcastle, UK) was verified using cell line protein lysates by standard Western blotting. The NCL-L-AK2 antibody detects specifically one band migrating at 45 kDa (data not shown). Before tumor specimen analyses the Aurora-A antibody NCL-L-AK2 was tested on tissue sections of normal breast and colon. Immunohistochemical assays on TMA block sections were then carried out with primary Aurora-A antibody as previously described (15) . Using an arbitrary cutoff, a strong, clearly positive staining pattern was classified as positive. No or faint staining pattern undetected by IHC digital image software was classified as negative. The software was written using ImageJ (http://rsb.info.nih.gov/ij/) and is based on the colour deconvolution principle as previously described (16) .
The cohort of tumors of this study has been previously analyzed for cytokeratin 5/14 (CK5/14) immunostaining pattern reflecting the basal tumor phenotype. A CK5/CK14 antibody cocktail was used in immunostaining analyses. Tumor specimens were classified as positive (basal phenotype) if >20% of the neoplastic cells showed cytoplasmic staining by this CK5/CK14 antibody cocktail (17) .
DNA sequencing and quantitative reverse transcriptasepolymerase chain reaction (qRT-PCR).
In order to study whether genomic mutations of AURKA are present in breast cancer cell lines, all exons (exons 1-9) were amplified using a standard PCR protocol. The oligonucleotide primers and specific PCR reaction conditions for each primer pair are available on request. Direct sequencing of PCR products was done using BigDye3 termination chemistry (Applied Biosystems, Foster City, CA) and an ABI 310 or 3100 genetic analyzer (Applied Biosystems) according to the manufacturer's instructions.
AURKA gene expression was studied using total RNA from breast cancer cell lines, which was reverse transcribed using Superscript II reverse transcriptase and random hexamer primer (Invitrogen, Life Technologies, USA). Primer and probe sequences were designed for Aurora-A and Cyclin B1, which was used as a control. Since the expression of Aurora-A is known to be cell cycle-dependent (18), we used Cyclin B1 as a reference gene due to its cell cycle dependence to adjust for the variation in the tumor proliferation rate (19) . The primer and probe sequences are available on request. The quantitative real-time RT-PCR reactions were performed with the Light Cycler (LC) (20) and the Light Cycler software was used in the analyses as previously described (14) . The quantitative real-time RT-PCR assays were repeated twice, and variation between runs was <15%. Detailed reaction conditions are available on request.
Results
Gene amplification by CISH and protein expression by IHC in clinical breast tumors.
Of the 126 primary sporadic breast tumors, 26 (21%) showed AURKA gene amplification by CISH (Fig. 1A) . AURKA gene amplification showed an association with basal-like tumor phenotype (Pearson ¯2, p=0.046) and a tendency towards PgR negativity (Pearson ¯2, p=0.086). In order to study correlation between AURKA gene amplification and basal tumor phenotype in more detail, we analyzed an additional series of 26 primary invasive ductal breast carcinomas of basal-like tumor pheno-type (i.e. showing positive cytokeratin 5/14 immunostaining). In this series 8/26 (31%) tumors showed AURKA gene amplification. Cross-tabulation of AURKA gene copy number status with clinicopathological characteristics is shown in Table I .
Aurora-A protein expression was analyzed by immunohistochemistry (n=97). Of these, 23 (24%) were positive and 74 (76%) were negative for Aurora-A antibody staining (Fig. 1C and D) . Aurora-A immunostaining pattern associated statistically significantly with AURKA gene amplification status (Pearson ¯2, p<0.0001; Table II) . AURKA gene copy number in the cell lines was analyzed by FISH (n=13). Gene amplification was detected in 6/13 (46%) of the cell lines, of which high level AURKA amplification (defined as AURKA/reference probe copy number ratio >2) was found in BT-474 and SK-BR-3 (2/13; 15%) and low level AURKA amplification (defined as AURKA/reference probe copy number ratio ~2) was found in four cell lines JIMT-1, MCF-7, UACC-812 and UACC-893 (4/13; 31%; ONCOLOGY REPORTS 23: 307-312, 2010 Table I . Clinicopathological association of AURKA gene amplification by CISH in breast tumors. Fig. 2 ). Aurora-A mRNA expression correlated significantly with gene copy number, but not with T91A polymorphism genotype (p<0.0001 and p=0.473, respectively; Fig. 3) .
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Discussion
In previous studies of breast cancer Aurora-A protein overexpression has been shown to correlate with aggressive clinicopathological parameters such as hormone receptor negativity and high histological grade (21, 22) . In our study a trend between AURKA gene amplification and progesterone receptor negativity was also seen. Interestingly, we showed that AURKA gene amplification was found in a significant proportion of tumors displaying basal-like tumor phenotype. Basal-like breast tumors account for approximately 10-15% of all breast cancers, characteristically express high-molecular weight basal cytokeratins and are considered as clinically aggressive tumors (23) . Amplification at 20q is a common chromosomal change in hereditary BRCA1 and BRCA2 breast and ovarian cancers (24, 25) and AURKA gene amplification has been associated with breast tumors harbouring a BRCA2 mutation (26) . These hereditary tumors, especially those in BRCA1 mutation carriers, are generally considered to belong to a basal-like subtype of breast cancer (17) . AURKA gene amplification, however, has not been correlated with basallike phenotype in sporadic breast tumors before. This novel finding may be of clinical importance, since basal-like breast tumors are aggressive and usually lack conventional therapeutic targets, such as hormone receptors or HER-2 (17, 27) . Based on the present study, patients with basal-like breast cancer might be candidates for future studies with Aurora-A inhibitors.
Among the cell lines analyzed in this study, in theory, JIMT-1 is a promising model system for testing the Aurora-A inhibitor molecules in basal-like tumors. Despite its paradoxical HER-2 positivity, JIMT-1 has constantly been classified as basal-like, mainly based on its strong overexpression of basal cytokeratins CK 5 and 14 (12) . In our study, JIMT-1 had additional resemblance to clinical basal-like tumors by showing both AURKA amplification and overexpression of Aurora-A mRNA. Since AURKA gene amplification is a more common phenomenon in breast cancer than basal-like pheno-type per se, it was expected to find AURKA gene amplification also in cell lines not filling criteria for basallike phenotype. This was true regarding breast cancer cell lines such as BT-474, SK-BR-3, MCF-7 and UACC-812 (28) . However, our results are in line with previously described studies showing AURKA gene amplification in the cell lines BT-474, SK-BR-3 and MCF-7 (3).
AURKA has been identified as one of the genes undergoing amplification in breast cancer already many years ago (3) . The association between gene amplification and overexpression in breast cancer, however, has remained contradictory (3, 5) . Our data obtained from breast cancer cell lines showed that AURKA gene amplification correlates strongly with Aurora-A mRNA level. We aimed at adjusting Aurora-A expression for differences in cell proliferation, which is a major determinant of Aurora-A mRNA levels (18) . In the present study, we showed that AURKA gene amplification associated with increased mRNA expression in breast cancer cell lines. In clinical tumors, gene amplification status was also associated with Aurora-A expression pattern. Gene amplification seemed to be the most significant factor explaining overexpression since positive staining was seen only in 14% of tumors in the absence of gene amplification. AURKA gene ---------------------------------------------------------------------------------------------------- a Aurora-A immunostaining pattern associated statistically significantly with AURKA gene amplification status (p<0.0001, ¯2 test).
b Gene amplification of AURKA was recorded when the ratio of AURKA signals compared to RP11-96L6 signals at 20p11.1-11.22 was ≥2.
- amplification was not always (40%) associated with positive immunostaining, and this finding can be partly explained by the complexity of 20q amplicon, the possible confounding effect of cell proliferation and the qualitative nature of immunohistochemistry.
Thus, strength of the present study is the use of a chromosome-arm specific reference probe, which made it possible to distinguish between true AURKA amplification and general polyploidy at 20q. To date it is well established that breast cancer tumors carry complex chromosomal rearrangements at 20q, often involving genes other than AURKA (29) . Limitations of the study include a relatively small clinical tumor sample size and the descriptive nature of the results concerning Aurora-A expression in clinical tumors.
We conclude that AURKA gene is frequently amplified in basal-like breast tumors, and gene amplification frequently leads to its overexpression. Basal-like breast tumors might be good candidates for future cancer therapy with Aurora-A inhibitors and the JIMT-1 cell line may be useful in experimental research with these potential anticancer molecules. 
